The expanded clearance extends BioTraceIO360 beyond liver applications to kidney procedures, advancing Techsomed’s vision of a multi-organ, AI-driven image-guided therapy platform that standardises minimally invasive cancer care.
Picard Medical (NYSE:PMI) announced today that it expanded its IP portfolio with a new U.S. patent for its next-generation artificial heart.
Cionic announced today that the FDA granted clearance for its second-generation product, the Neural Sleeve 2.
Virtuoso Surgical announced today that it received FDA breakthrough device designation for bladder lesion removal with its surgical robot.
Heartflow (Nasdaq:HTFL) announced that it received FDA 510(k) clearance for its next-generation Heartflow Plaque Analysis algorithm.
Techsomed this week announced it received FDA 510(k) clearance to expand indications for its BioTraceIO360 software platform to include percutaneous ablation of soft tissue in the kidney.
Medtronic (NYSE: MDT)+
announced today that it received FDA approval for its Altaviva neuromodulation device.
CAESAREA, Israel, Sept. 18, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent titled “Cryoprobe”.
The company is working to obtain CE marking of the system in the European Union.
OrganOx announced today that it received FDA approval for the use of its normothermic machine perfusion (NMP) device during air transport.